A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

Semaglutide (sold under the brand names Wegovy and Ozempic) and tirzepatide (sold under the brand names Zepbound and Mounjaro ... (glycemic control) in a real-world setting.

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

In the real world, the use of semaglutide (Wegovy) and tirzepatide (Zepbound) produce far less ... which confirms the efficacy of this medications for the prevention of type 2 diabetes but also ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients to adapt on the fly.